Ultra-High Resolution Brain PET: A 'Quantum Leap' for Neuroradiology
In a recent interview at the SNMMI conference, Roger Lecomte, Ph.D., and Vincent Doyon discussed the advent of ultra-high resolution (UHR) brain positron emission tomography (PET), which reportedly offers double the spatial resolution of conventional PET and may facilitate earlier detection of Alzheimer’s disease and other conditions.
How Radiology Facilities Can Help Reduce Health-Care Associated Infections
July 13th 2023Noting recent double-digit increases in health-care associated infections (HAIs) and potential vulnerabilities in radiology departments, this author emphasizes proactive preventive measures to protect patients and staff.
Can an Emerging System Have an Impact in Assessing Treatment Response for Prostate Cancer?
Examining the use of the Response Evaluation Criteria in Prostate-specific Membrane Antigen (PSMA) PET/CT (RECIP 1.0) model for assessing the treatment of metastatic castration-resistant prostate cancer, researchers found robust agreement between quantitative application of RECIP via tumor segmentation software and qualitative application of the model through reads by nuclear medicine physicians.
Study Says Photon-Counting CT Offers Better Lung Assessment than Conventional CT
For conditions ranging from interstitial lung disease and post-COVID-19 complications to idiopathic pulmonary fibrosis, photon-counting computed tomography (PCCT) facilitates simultaneous functional and morphologic lung assessment at lower radiation dosing than conventional chest CT, according to newly published research.
The Rise of NPP Image Interpretation: What New Radiology Research Reveals
In a retrospective review of over 110 million imaging claims for patients with commercial insurance or Medicare Advantage, researchers noted key trends signaling significant increases in imaging billed by non-physician practitioners (NPPs).
Can Pre-Op MRI Staging Help Predict Prostate Cancer Recurrence after a Prostatectomy?
Patients with extraprostatic extension (EPE) on pre-prostatectomy MRI had a 3.6-fold higher risk for biochemical recurrence (BCR) of prostate cancer and a 25 percent lower three-year BCR-free survival rate in comparison to patients without EPE on pre-op MRI, according to newly published research.
Emerging PET Radiotracer May Improve Detection of Coronary Artery Disease in Obese Patients
In a recent interview at the SNMMI conference, Krishna Patel, M.D., discussed the benefits of the PET perfusion radiotracer agent 18F-flurpiridaz and new research findings showing the agent’s increased sensitivity and specificity in diagnosing coronary artery disease in obese patients.
Ultromics Gets HCPCS Code for AI-Powered EchoGo Heart Failure Device
An artificial intelligence (AI)-enabled platform that can reportedly diagnose heart failure with preserved ejection fraction (HFpEF) through analysis of a single echocardiogram view, the EchoGo Heart Failure now has a HCPCS code for use of the technology in outpatient settings for Medicare beneficiaries.
Can SPECT/CT Guidance Facilitate Personalized Dosing for Patients with Prostate Cancer?
The use of single-photon emission computed tomography (SPECT)/computed tomography (CT) to monitor the effectiveness of Lu-177-PSMA (Pluvicto) in treating prostate cancer led to a greater than 50 percent decrease in prostate-specific antigen (PSA) level for 60 percent of patients in a new study, noted Andrew Nguyen, MBBS, FRACP, AANMS, in a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.
Clarity Pharmaceuticals to Begin Phase 3 Trial for New PSMA PET Agent for Prostate Cancer
The prospective multicenter trial, which is slated to begin patient recruitment in late 2023, will reportedly assess the ability of 64Cu SAR-bisPSMA to diagnose prostate cancer within pelvic lymph nodes.
Icometrix Gets First CPT III Code Issued by AMA for AI Brain MRI Software
Reportedly receiving the first Current Procedural Terminology (CPT) III code from the American Medical Association (AMA) for artificial intelligence (AI)-enabled brain magnetic resonance imaging (MRI) software, Icometrix says its adjunctive quantification software can be utilized for diagnosis and assessment of conditions ranging from Alzheimer’s disease and epilepsy to stroke and dementia.
The Radiologist and the Multitude
July 3rd 2023While it stands to reason that referring physicians would prefer a condensed summary of relevant imaging findings, vagaries with insurers, patients and other possible readers of the radiology report may warrant an inefficient minutiae-cluttered approach.